Long‐term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow‐up of the JLSG‐96/02 studies

Summary Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasia derived from immature myeloid dendritic cells with the mitogen‐activated protein kinase (MAPK) pathway gene mutation. LCH is rarely fatal, but patients develop various permanent consequences (PCs). We report the frequencies of LCH‐related PCs in paediatric patients ( n = 317) treated by the JLSG‐96/02 AraC‐containing regimens. One‐third of LCH patients had at...